Standard treatments, including surgery, radiotherapy, and temozolomide, provide limited survival benefits, largely due to therapy evasion mechanisms such as GBM stem cell survival, P-glycoprotein activity, and MGMT overexpression, leading to recurrence and resistance. The gene discussed is ABCB1; the disease is glioblastoma.